Los Angeles Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$542K Hold
4,730
– – ﹤0.01% 894
2026
Q1
$394K Buy
4,730
+2,762
+140% +$219K ﹤0.01% 947
2025
Q4
$121K Buy
+1,968
New +$133K ﹤0.01% 1370
2024
Q2
– Sell
-5,911
Closed -$238K – 1233
2024
Q1
$238K Sell
5,911
-3,737
-39% -$134K ﹤0.01% 1069
2023
Q4
$246K Buy
+9,648
New +$173K ﹤0.01% 1063
2023
Q3
– Sell
-9,648
Closed -$222K – 1183
2023
Q2
$222K Buy
+9,648
New +$276K ﹤0.01% 1098

Other funds holding KYMR

Los Angeles Capital Management's KYMR Position: Q2 2026 in Review

Los Angeles Capital Management held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 4,730 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #894.

Los Angeles Capital Management first reported a position in KYMR in Q2 2023 and has held it in 6 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Los Angeles Capital Management held 4,730 shares of Kymera Therapeutics worth $542K as of Q2 2026.
  • Los Angeles Capital Management left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #894 holding.
  • Los Angeles Capital Management first reported a position in Kymera Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.